Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion
Animal research · 2002
- What was studied
- Experimental myocardial reperfusion
- Main finding
- The experimental report describes prevention of ventricular arrhythmias when Dalargin or DADLE was given before coronary reperfusion. It investigates opioid-receptor involvement rather than establishing a clinical antiarrhythmic treatment.
Reported findings and study design
Coronary-reperfusion experiment: Dalargin or DADLE 0.1 mg/kg immediately before reperfusion.
Population or model Experimental myocardial reperfusion
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Ventricular arrhythmias | Prevention reported | |
| μ-receptor blockade | Abolished the antiarrhythmic effect |
Numerical arrhythmia counts not supplied in the indexed abstract.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Preclinical model; no human treatment benefit established.
- DADLE and Dalargin are distinct peptides.
Source details
Selected source text and metadata checked; full risk-of-bias review pending.
Selected text reviewed
Sources checked
Citation
Author unconfirmed. Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion Indexed original publication; PMID 12124638